Business Description
Novartis AG
NAICS : 325412
ISIN : US66987V1098
Share Class Description:
FRA:NOTA: ADRDescription
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.44 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.74 | |||||
| Debt-to-EBITDA | 1.58 | |||||
| Interest Coverage | 14.37 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.79 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.6 | |||||
| 3-Year FCF Growth Rate | 4.2 | |||||
| 3-Year Book Growth Rate | -3.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.93 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.11 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.46 | |||||
| 9-Day RSI | 33.98 | |||||
| 14-Day RSI | 37.65 | |||||
| 6-1 Month Momentum % | 13.88 | |||||
| 12-1 Month Momentum % | 20.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.9 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 169.69 | |||||
| Days Sales Outstanding | 55.82 | |||||
| Days Payable | 123.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.61 | |||||
| Dividend Payout Ratio | 0.65 | |||||
| 3-Year Dividend Growth Rate | 3.8 | |||||
| Forward Dividend Yield % | 3.61 | |||||
| 5-Year Yield-on-Cost % | 3.93 | |||||
| 3-Year Average Share Buyback Ratio | 3.2 | |||||
| Shareholder Yield % | 6.89 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.92 | |||||
| Operating Margin % | 27.26 | |||||
| Net Margin % | 35.14 | |||||
| FCF Margin % | 24.98 | |||||
| ROE % | 41.66 | |||||
| ROA % | 17.16 | |||||
| ROIC % | 13.56 | |||||
| 3-Year ROIIC % | -1.76 | |||||
| ROC (Joel Greenblatt) % | 127 | |||||
| ROCE % | 19.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.44 | |||||
| Forward PE Ratio | 12.69 | |||||
| PE Ratio without NRI | 18.42 | |||||
| Shiller PE Ratio | 17.53 | |||||
| Price-to-Owner-Earnings | 10.3 | |||||
| PS Ratio | 4.34 | |||||
| PB Ratio | 5.03 | |||||
| Price-to-Free-Cash-Flow | 17.36 | |||||
| Price-to-Operating-Cash-Flow | 13.59 | |||||
| EV-to-EBIT | 16.77 | |||||
| EV-to-Forward-EBIT | 12.71 | |||||
| EV-to-EBITDA | 11.66 | |||||
| EV-to-Forward-EBITDA | 10.62 | |||||
| EV-to-Revenue | 4.6 | |||||
| EV-to-Forward-Revenue | 4.27 | |||||
| EV-to-FCF | 18.46 | |||||
| Price-to-Projected-FCF | 1.37 | |||||
| Price-to-Median-PS-Value | 1.11 | |||||
| Earnings Yield (Greenblatt) % | 5.96 | |||||
| FCF Yield % | 5.88 | |||||
| Forward Rate of Return (Yacktman) % | 9.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 45,775.052 | ||
| EPS (TTM) (€) | 7.82 | ||
| Beta | 0.37 | ||
| Volatility % | 14.18 | ||
| 14-Day RSI | 37.65 | ||
| 14-Day ATR (€) | 1.642335 | ||
| 20-Day SMA (€) | 102.19 | ||
| 12-1 Month Momentum % | 20.69 | ||
| 52-Week Range (€) | 85.6 - 108.5 | ||
| Shares Outstanding (Mil) | 1,999.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis AG Frequently Asked Questions
What is Novartis AG(FRA:NOTA)'s stock price today?
The current price of FRA:NOTA is €97.20. The 52 week high of FRA:NOTA is €108.50 and 52 week low is €85.60.
When is next earnings date of Novartis AG(FRA:NOTA)?
The next earnings date of Novartis AG(FRA:NOTA) is 2025-01-31.
Does Novartis AG(FRA:NOTA) pay dividends? If so, how much?
The Dividend Yield %  of Novartis AG(FRA:NOTA) is 3.61% (As of Today), Highest Dividend Payout Ratio of Novartis AG(FRA:NOTA) was 1.19. The lowest was 0.33. And the median was 0.85. The  Forward Dividend Yield % of Novartis AG(FRA:NOTA) is 3.61%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers